Psilera Inc. Advances Alcohol Use Disorder Research
Psilera Inc. is making significant strides in the field of neuroplasticity as it embarks on a groundbreaking study focused on treating Alcohol Use Disorder (AUD). This endeavor is backed by a notable Small Business Innovation Research Grant, which aims to propel the development of a novel neuroplastogen toward Investigational New Drug (IND) status.
Funding for Innovative Solutions
The funding, amounting to up to $2 million, comes from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and is structured around specific milestones over a three-year period. This grant highlights the government's commitment to supporting innovative research focused on developing effective treatments for AUD, a condition that affects millions of adults.
Impact of AUD
Approximately 30 million adults in the U.S. suffer from AUD, yet only about 8% actively seek treatment. The stark reality of this statistic emphasizes a profound need for new therapeutic options that can facilitate recovery and support patients in overcoming addiction.
Psilera's Research Vision
Psilera aims to meet this critical need by advancing its unique neuroplastogen, derived from psilocybin, to provide a new treatment avenue. This innovative compound works by reshaping neuronal pathways in the brain, which may assist individuals in breaking detrimental thought and behavior patterns associated with alcohol dependency.
Potential of Neuroplastogens
Dr. Jackie von Salm, Co-founder and Chief Scientific Officer, expressed gratitude towards the NIH for their ongoing support. She mentioned how neuroplastogens hold immense promise in altering the course of various debilitating illnesses, including addiction. The research funded by this grant could reshape the way AUD is treated, potentially offering a non-hallucinogenic and non-addictive alternative for patients.
Promising Pre-Clinical Results
In pre-clinical studies, preliminary results indicate that Psilera's psilocybin derivative could serve as a groundbreaking non-opioid treatment for reducing alcohol consumption. This compound was strategically selected from an extensive library during a targeted screening campaign focused on interacting with serotonin receptor 5-HT2A and positively influencing the brain's serotonergic pathways.
Advantages of the New Therapy
If successful, Psilera’s approach could enable patients to administer their treatment at home, mitigating the stigma typically associated with addiction therapy. This innovative route may empower individuals to seek help unobtrusively and promote healthier lifestyle changes without the fear of traditional treatment barriers.
About Psilera Inc.
Psilera Inc. is dedicated to revolutionizing medicine by leveraging the potential of natural products to develop advanced neuroplastic therapies. Founded with the vision of transforming the treatment landscape for neurodegenerative diseases and addictions, the company boasts a robust pipeline of next-generation therapies. One of its pioneering products is PSIL-006, aimed at treating frontotemporal dementia (FTD), showcasing Psilera’s commitment to innovating treatment options for complex neurological conditions.
Contact Information
If you're interested in learning more about Psilera's breakthroughs or the clinical developments around AUD treatment, feel free to reach out.
Media Contact:
Psilera Inc.
Michael Lauer
MDL Strategic Communications
Email: michael@mdlcomms.com
Frequently Asked Questions
What is the purpose of the NIH grant awarded to Psilera Inc.?
The NIH grant aims to support Psilera in researching new treatments for Alcohol Use Disorder (AUD) using neuroplastogens.
How much funding did Psilera receive from the NIH?
Psilera received a grant of up to $2 million from the National Institute on Alcohol Abuse and Alcoholism.
Who is the Chief Scientific Officer at Psilera?
Dr. Jackie von Salm is the Co-founder and Chief Scientific Officer at Psilera Inc.
What therapeutic alternative is Psilera developing?
Psilera is developing a psilocybin-derived neuroplastogen aimed at treating Alcohol Use Disorder without the hallucinogenic effects.
What is the significance of the psilocybin derivative in Psilera's research?
This derivative has shown promise as a non-opioid treatment in pre-clinical studies, targeting brain pathways affected by AUD.
